SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. scores highest on Torque (69) and lowest on Price (39). Its PosiPenta is 47.84 out of 100, around the middle of similar companies.
On the Penta Grid this week, SAB Biotherapeutics, Inc. is Grid #318 of 837 in the Healthcare sector in United States, and Grid #2,128 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. | 47.84 | 39 | 42 | 44 | 69 | 46 |
| Treace Medical Concepts, Inc. | 39.41 | 17 | 39 | 61 | 28 | 52 |
| Fulcrum Therapeutics, Inc. | 43.88 | 40 | 52 | 27 | 65 | 35 |
| InfuSystem Holdings, Inc. | 58.99 | 33 | 61 | 95 | 60 | 45 |
| ClearPoint Neuro, Inc. | 23.73 | 2 | 34 | 28 | 9 | 46 |
| Anika Therapeutics, Inc. | 64.30 | 29 | 83 | 89 | 59 | 61 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.96 |
| P/B ratio | 1.07 |
EEarnings
| Trailing EPS | ₹-122.18 |
| Forward EPS | ₹-90.38 |
NNitro
| Price | 239.63 |
| 52-week high | 487.78 |
| 52-week low | 198.90 |
| Fall from 52-week high | 50.9% |
TTorque
| Return on equity (ROE) | -11.27% |
| Debt-to-equity | 0.02 |
AAnchor
| Beta (price swings) | 0.58 |
| Market cap | ₹2,180 Cr |
| Insider holding | 0.71% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is SAB Biotherapeutics, Inc.'s PosiPenta score?
SAB Biotherapeutics, Inc.'s PosiPenta is 47.84 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does SAB Biotherapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, SAB Biotherapeutics, Inc. is Grid #318 of 837 in the Healthcare sector in United States, and Grid #2,128 of 4,000 in United States.
Which PosiPenta pillar is strongest for SAB Biotherapeutics, Inc.?
Torque (durability), with a score of 69 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for SAB Biotherapeutics, Inc.?
Price (valuation), with a score of 39 out of 100: weaker than most similar companies.
Has SAB Biotherapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.53 points, from 44.31 to 47.84.
PositoAI is for research and education only and is not investment advice.